Advice
Following a full submission.
Pemetrexed (Alimta) is not recommended for use within NHS Scotland as a monotherapy for second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer.
Pemetrexed appears to have comparable efficacy and possibly a more favourable toxicity profile compared to another agent used in second–line treatment of non-small cell lung cancer.
However, the economic case has not been demonstrated.
Download detailed advice150KB (PDF)
Medicine details
- Medicine name:
- pemetrexed, 500mg, powder for reconstitution (Alimta)
- SMC ID:
- 342/07
- Indication:
- Locally advanced or metastatic non-small cell lung cancer.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 12 February 2007